Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

Autor: Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J.J.W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., Van der Klift, M., Van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W.M., Van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J.F.M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Giovanni, San, Stuessi, Georg, Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M. G., van de Loosdrecht, A., Janssen, J. J.W.M., van Esser, J. W.J., Brouwer, R. E., Van Lammeren-Venema, D., Levin, M. D., Tick, L. W., Legdeur, M. C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J. H., von dem Borne, P. A., Schouten, H. C., Cornelissen, J., Wouters, B., Raaijmakers, H. G.M., Kuball, J.
Přispěvatelé: Hematology laboratory, CCA - Cancer Treatment and quality of life, Hematology
Jazyk: angličtina
Rok vydání: 2020
Zdroj: Leukemia, 34(10). Nature Publishing Group
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
ISSN: 0887-6924
DOI: 10.1038/s41375-020-0725-0)
Popis: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Databáze: OpenAIRE
Externí odkaz: